SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (22269)6/15/1998 3:38:00 PM
From: Pseudo Biologist  Respond to of 32384
 
Mudcat, the link requires free registration. You may have to go to plain medscape.com first and go thru the registration routine. The site is informative in general.

I do not recall Panretin being mentioned at all in the online version of the article (I never saw the print version).

The gist of the article is that the wider use of HAART (Highly Active Anti-Retroviral Therapy, or something close; essentially triple therapy against HIV) has resulted in reduced relative occurrence of Kaposi's sarcoma (KS). It's not clear if the patients are "cured" of KS, or if it's just a temporary bounce after their immune system recovers. If the latter, then Panretin may be useful even for these patients.

PB



To: Mudcat who wrote (22269)6/15/1998 4:21:00 PM
From: Hippieslayer  Read Replies (1) | Respond to of 32384
 
MC, many HIV infected patients who are taking Prot Inhib, are not getting KS. That is a problem for lgnd. Funny, patients on PI are developing localized and concentrated fat deposits on their body. If lgnd can create a drug to combat this affect......


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News